ArticleProceedings of the National Academy of Sciences of the United States of America2014
Molecular mechanism for differential recognition of membrane phosphatidylserine by the immune regulatory receptor Tim4.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 76 citations in OpenAlex.
- The Efferocytosis-Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment.MedComm · 2026Review
- Recombinant protein platform for high-throughput investigation of peptide-liposome interactions via fluorescence anisotropy depolarization.Communications chemistry · 2026Article
- Phosphatidylserine exposure on tolerogenic nanoparticle correlate with oral tolerance.Scientific reports · 2025Article
- Binding equations for the lipid composition dependence of peripheral membrane-binding proteins.Biophysical journal · 2024Article
- Engineered EVs designed to target diseases of the CNS.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2/PI3K/AKT/OPA1 axis.Cell death & disease · 2023Article
- Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice.Nature communications · 2023Article
- Phosphatidylserine-mediated oral tolerance.Cellular immunology · 2023Article
- Biophysical Characterization of Tolerogenic Lipid-Based Nanoparticles Containing Phosphatidylcholine and Lysophosphatidylserine.Journal of pharmaceutical sciences · 2022Article
- Exosomal Composition, Biogenesis and Profiling Using Point-of-Care Diagnostics-Implications for Cardiovascular Disease.Frontiers in cell and developmental biology · 2022Review
- How Tim proteins differentially exploit membrane features to attain robust target sensitivity.Biophysical journal · 2021Article
- Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A.Journal of thrombosis and haemostasis : JTH · 2021Article
- Phosphatidylserine binding directly regulates TIM-3 function.The Biochemical journal · 2021Article
- Optimization of Sentinel Lymph Node Imaging Methodology Using Anionic Liposome and Hyaluronidase.Pharmaceutics · 2021Article
- Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins.Scientific reports · 2021Article
- MARCOBiomedicines · 2021Article
- Enveloped RNA virus utilization of phosphatidylserine receptors: Advantages of exploiting a conserved, widely available mechanism of entry.PLoS pathogens · 2021Review
- Development of a blocker of the universal phosphatidylserine- and phosphatidylethanolamine-dependent viral entry pathways.Virology · 2021Article
- Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities.Frontiers in cell and developmental biology · 2021Review
- Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles.Immunological investigations · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Recognition of phosphatidylserine (PS) lipids exposed on the extracellular leaflet of plasma membranes is implicated in both apoptotic cell removal and immune regulation. The PS receptor T cell immunoglobulin and mucin-domain-containing molecule 4 (Tim4) regulates T-cell immunity via phagocytosis of both apoptotic (high PS exposure) and nonapoptotic (intermediate PS exposure) activated T cells. The latter population must be removed at lower efficiency to sensitively control immune tolerance and memory cell population size, but the molecular basis for how Tim4 achieves this sensitivity is unknown. Using a combination of interfacial X-ray scattering, molecular dynamics simulations, and membrane binding assays, we demonstrate how Tim4 recognizes PS in the context of a lipid bilayer. Our data reveal that in addition to the known Ca(2+)-coordinated, single-PS binding pocket, Tim4 has four weaker sites of potential ionic interactions with PS lipids. This organization makes Tim4 sensitive to PS surface concentration in a manner capable of supporting differential recognition on the basis of PS exposure level. The structurally homologous, but functionally distinct, Tim1 and Tim3 are significantly less sensitive to PS surface density, likely reflecting the differences in immunological function between the Tim proteins. These results establish the potential for lipid membrane parameters, such as PS surface density, to play a critical role in facilitating selective recognition of PS-exposing cells. Furthermore, our multidisciplinary approach overcomes the difficulties associated with characterizing dynamic protein/membrane systems to reveal the molecular mechanisms underlying Tim4's recognition properties, and thereby provides an approach capable of providing atomic-level detail to uncover the nuances of protein/membrane interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.